Making (anti-) sense out of huntingtin levels in Huntington disease

Molecular Neurodegeneration

Volumn 10, Issue 1, 2015, Pages

  Evers, Melvin M ^a   Schut, Menno H ^a   Pepers, Barry A ^a   Atalar, Melek ^b   Van Belzen, Martine J ^a   Faull, Richard Lm ^c   Roos, Raymund Ac ^a   Van Roon Mom, Willeke Mc ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Galapagos BV   (Netherlands)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

HD patient derived fibroblasts; Huntingtin; Huntingtin antisense transcript; Huntington disease; Juvenile HD; Post mortem HD brain tissue

Indexed keywords

HUNTINGTIN; MESSENGER RNA; HTT PROTEIN, HUMAN; MUTANT PROTEIN; NERVE PROTEIN;

ADULT; AGED; ARTICLE; BRAIN HOMOGENATE; BRAIN TISSUE; CAG REPEAT; CHILD; CONTROLLED STUDY; EXON; FEMALE; FIBROBLAST; FRONTAL CORTEX; HUMAN; HUMAN TISSUE; HUNTINGTON CHOREA; MALE; MIDDLE AGED; MIDDLE TEMPORAL GYRUS; ONSET AGE; PRESCHOOL CHILD; PROTEIN AGGREGATION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM; VERY ELDERLY; WESTERN BLOTTING; YOUNG ADULT; AUTOPSY; BRAIN; GENETICS; METABOLISM; PATHOLOGY;

ANIMALIA;

AUTOPSY; BRAIN; FIBROBLASTS; HUMANS; HUNTINGTON DISEASE; MUTANT PROTEINS; NERVE TISSUE PROTEINS; RNA, MESSENGER;

EID: 84928546289     PISSN: None     EISSN: 17501326     Source Type: Journal    
DOI: 10.1186/s13024-015-0018-7     Document Type: Article

References (28)

1. Roos RA. Huntington's disease: a clinical review. Orphanet J Rare Dis. 2010;5:40.
2. Kremer B, Weber B, Hayden MR. New insights into the clinical features, pathogenesis and molecular genetics of Huntington disease. Brain Pathol. 1992;2:321-35.
3. Losekoot M, van Belzen MJ, Seneca S, Bauer P, Stenhouse SA, Barton DE. EMQN/CMGS best practice guidelines for the molecular genetic testing of Huntington disease. Eur J Hum Genet. 2013;21:480-6.
4. Vonsattel JP, DiFiglia M. Huntington disease. J Neuropathol Exp Neurol. 1998;57:369-84.
5. Difiglia M, Sapp E, Chase KO, Davies SW, Bates GP, Vonsattel JP, et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science. 1997;277:1990-3.
6. Lee JM, Galkina EI, Levantovsky RM, Fossale E, Anne AM, Gillis T, et al. Dominant effects of the Huntington's disease HTT CAG repeat length are captured in gene-expression data sets by a continuous analysis mathematical modeling strategy. Hum Mol Genet. 2013;22:3227-38.
7. Krauss S, Griesche N, Jastrzebska E, Chen C, Rutschow D, Achmuller C, et al. Translation of HTT mRNA with expanded CAG repeats is regulated by the MID1-PP2A protein complex. Nat Commun. 2013;4:1511.
8. Chung DW, Rudnicki DD, Yu L, Margolis RL. A natural antisense transcript at the Huntington's disease repeat locus regulates HTT expression. Hum Mol Genet. 2011;20:3467-77.
9. Liu W, Chaurette J, Pfister EL, Kennington LA, Chase KO, Bullock J, et al. Increased Steady-State Mutant Huntingtin mRNA in Huntington's Disease Brain. J Huntingtons Dis. 2013;2:491-500.
10. Stine OC, Li SH, Pleasant N, Wagster MV, Hedreen JC, Ross CA. Expression of the mutant allele of IT-15 (the HD gene) in striatum and cortex of Huntington's disease patients. Hum Mol Genet. 1995;4:15-8.
11. Liu W, Kennington LA, Rosas HD, Hersch S, Cha JH, Zamore PD, et al. Linking SNPs to CAG repeat length in Huntington's disease patients. Nat Methods. 2008;5:951-3.
12. Legleiter J, Mitchell E, Lotz GP, Sapp E, Ng C, DiFiglia M, et al. Mutant huntingtin fragments form oligomers in a polyglutamine length-dependent manner in vitro and in vivo. J Biol Chem. 2010;285:14777-90.
13. Sathasivam K, Woodman B, Mahal A, Bertaux F, Wanker EE, Shima DT, et al. Centrosome disorganization in fibroblast cultures derived from R6/2 Huntington's disease (HD) transgenic mice and HD patients. Hum Mol Genet. 2001;10:2425-35.
14. Persichetti F, Carlee L, Faber PW, Mcneil SM, Ambrose CM, Srinidhi J, et al. Differential expression of normal and mutant Huntington's disease gene alleles. Neurobiol Dis. 1996;3:183-90.
15. Gonitel R, Moffitt H, Sathasivam K, Woodman B, Detloff PJ, Faull RL, et al. DNA instability in postmitotic neurons. Proc Natl Acad Sci U S A. 2008;105:3467-72.
16. Quarrell O, O'Donovan KL, Bandmann O, Strong M. The Prevalence of Juvenile Huntington's Disease: A Review of the Literature and Meta-Analysis. PLoS Curr. 2012;4:e4f8606b742ef3.
17. Pouladi MA, Morton AJ, Hayden MR. Choosing an animal model for the study of Huntington's disease. Nat Rev Neurosci. 2013;14:708-21.
18. Sopher BL, Ladd PD, Pineda VV, Libby RT, Sunkin SM, Hurley JB, et al. CTCF regulates ataxin-7 expression through promotion of a convergently transcribed, antisense noncoding RNA. Neuron. 2011;70:1071-84.
19. Kordasiewicz HB, Stanek LM, Wancewicz EV, Mazur C, McAlonis MM, Pytel KA, et al. Sustained Therapeutic Reversal of Huntington's Disease by Transient Repression of Huntingtin Synthesis. Neuron. 2012;74:1031-44.
20. Rigamonti D, Bauer JH, De-Fraja C, Conti L, Sipione S, Sciorati C, et al. Wild-type huntingtin protects from apoptosis upstream of caspase-3. J Neurosci. 2000;20:3705-13.
21. Zhang Y, Li M, Drozda M, Chen M, Ren S, Mejia Sanchez RO, et al. Depletion of wild-type huntingtin in mouse models of neurologic diseases. J Neurochem. 2003;87:101-6.
22. Dragatsis I, Levine MS, Zeitlin S. Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice. Nat Genet. 2000;26:300-6.
23. Appl T, Kaltenbach L, Lo DC, Terstappen GC. Targeting mutant huntingtin for the development of disease-modifying therapy. Drug Discov Today. 2012;17:1217-23.
24. Warner JP, Barron LH, Brock DJ. A new polymerase chain reaction (PCR) assay for the trinucleotide repeat that is unstable and expanded on Huntington's disease chromosomes. Mol Cell Probes. 1993;7:235-9.
25. Spiess AN, Ivell R. A highly efficient method for long-chain cDNA synthesis using trehalose and betaine. Anal Biochem. 2002;301:168-74.
26. Evers MM, Tran HD, Zalachoras I, Meijer OC, den Dunnen JT, van Ommen GJ, et al. Preventing formation of toxic N-terminal huntingtin fragments through antisense oligonucleotide-mediated protein modification. Nucleic Acid Ther. 2014;24:4-12.
27. Hu J, Matsui M, Gagnon KT, Schwartz JC, Gabillet S, Arar K, et al. Allele-specific silencing of mutant huntingtin and ataxin-3 genes by targeting expanded CAG repeats in mRNAs. Nat Biotechnol. 2009;27:478-84.
28. Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP. Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol. 1985;44:559-77.